Food composition and anti-obesity composition

Abstract

The present invention addresses the problem of providing a food composition and an anti-obesity composition which have a small intake per day and which reduce the fat area of the abdomen. According to the present invention, provided are a food composition and an anti-obesity composition, each of which contains an extract of a plant belonging to the genus Malaytea, an extract of green tea, and an extract of African Amomum.

Description

Technical Field

[0001] The present invention relates to a food composition and an anti-obesity composition. Background Art

[0002] In recent years, the proportion of obese people has increased not only in Japan but also in the world. An oral composition having the effect and function of inhibiting obesity or weight gain is required. Obesity refers to a state of excessive accumulation of adipose tissue in the viscera or subcutaneous tissue. Obesity has a great influence on the organism, and there are many diseases believed to be caused by obesity. When preventing obesity, inhibition of the accumulation of visceral fat can be cited. If there is an oral composition that inhibits obesity or weight gain, it is possible to control body weight more simply. From this viewpoint, various active ingredients or compositions have been proposed to inhibit obesity or weight gain. When the active ingredient is derived from a natural product, sometimes compared with a chemically synthesized active ingredient, there are fewer side effects or psychological resistance, and it is easy for the demander to use.

[0003] The following are disclosed as composite ingredient supplements containing Salacia plant extracts:

[0004] A complex ingredient supplement A tablet containing salacinol (1.0 mg) derived from Salacia, green tea extract (related ingredient: epigallocatechin gallate 11.0 mg), enzyme-treated rutin (related ingredient: monoglucosylrutin 1.8 mg), and dietary fiber (related ingredient: indigestible dextrin (dietary fiber) 760 mg); and a complex ingredient supplement B tablet containing salacinol (1.0 mg) derived from Salacia, green tea extract (related ingredient: epigallocatechin gallate 8.0 mg), enzyme-treated rutin (related ingredient: monoglucosylrutin 1.8 mg), dietary fiber (related ingredient: indigestible dextrin (dietary fiber) 800 mg), and seaweed polyphenols (related ingredient: brown algae polyphenols 4.0 mg).

[0005] Furthermore, it is disclosed that body weight, BMI, visceral fat area, total fat area, etc. can be reduced by taking a composite ingredient compound supplement (for example, page 35 of Non-Patent Document 1).

[0006] Disclosed is an extract of Aframomum mel egueta, a plant of the ginger family, or aframomum alcohol, a component contained in Aframomum. In a dietary food composition, it is disclosed that the intake per adult is 20 to 1000 mg in terms of aframomum alcohol, and results related to promoting fat decomposition and inhibiting weight gain when supplied to mouse cells or mice are disclosed (for example, Patent Document 1).

[0007] Previous technical literature

[0008] Patent Literature

[0009] Patent Document 1: Japanese Patent No. 4819171

[0010] Non-patent literature

[0011] Non-patent document 1: Consumer Affairs Agency’s food information search for food with functional properties, application number D677 Form V: Scientific basis for functionality (https: / / www.fld.caa.go.jp / caaks / cssc06 / youshiki5?yousiki5216File=D677%255CD677_youshiki5.pdf) Summary of the invention

[0012] Technical issues to be solved by the invention

[0013] Generally, oral compositions containing multiple different active ingredients with desired effects / functions are known. When designing such oral compositions, it is necessary to study the mechanism of action, interaction, and dosage of multiple different active ingredients in the body. Generally, in oral compositions, when multiple different active ingredients are used, the types or contents of the active ingredients increase, and the additives used for dispersion or stabilization of each active ingredient are also different, so the daily intake in the oral composition sometimes increases. As a result, the subject feels that it is difficult to swallow the oral composition.

[0014] As a result of in-depth research conducted by the present inventors, it was found that an oral composition containing a Salacia plant extract, catechins and 6-african myristol has the effect of reducing at least one of body weight, body fat percentage, BMI, waist circumference and abdominal fat area (visceral fat area, subcutaneous fat area, total fat area) with a small daily intake, thereby completing the present invention.

[0015] Furthermore, the present inventors discovered in another embodiment that an oral composition containing a Salacia plant extract, catechins and 6-african myristol has the effect of reducing at least one of body weight, body fat percentage, BMI, waist circumference and abdominal fat area (visceral fat area, subcutaneous fat area, total fat area) with a small daily intake, and the effect of suppressing the increase in blood pressure which is one of the causes of metabolic syndrome, thereby completing the present invention.

[0016] Therefore, an object of the present invention is to provide a food composition or an anti-obesity composition that can reduce at least one of body weight, body fat percentage, BMI, waist circumference and abdominal fat area (visceral fat area, subcutaneous fat area, total fat area) with a small daily intake.

[0017] Another object of the present invention is to provide a food composition or an anti-obesity composition that can reduce at least one of body weight, body fat percentage, BMI, waist circumference and abdominal fat area (visceral fat area, subcutaneous fat area, total fat area) with a small daily intake, and inhibit the increase in blood pressure.

[0018] Means for solving technical problems

[0019] The present invention is as follows.

[0020] [0] An oral composition comprising a Salacia plant extract, a green tea extract and a African cardamom extract.

[0021] [1] A food composition comprising a Salacia plant extract, a green tea extract and a Paeonia lactiflora extract.

[0022] [2] The food composition according to [1], wherein

[0023] The mass ratio of the Salacia plant extract, the green tea extract and the African cardamom extract is 1-50:3-30:1-5.

[0024] [3] The food composition according to [1] or [2], wherein

[0025] The active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarracenol, epigallocatechin gallate and 6-aframomide, respectively, and the daily intake of these is 0.2-1.5 mg, 10-100 mg and 1-5 mg, respectively.

[0026] [4] The food composition according to [1] or [2], wherein

[0027] The active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarracenol, epigallocatechin gallate and 6-aframomide, respectively, and the daily intakes thereof are 0.04 to 2.1 mg, 10 to 100 mg and 1 to 5 mg, respectively.

[0028] [5] The food composition according to any one of [1] to [4], wherein

[0029] Green tea extract is epigallocatechin gallate.

[0030] [6] The food composition according to any one of [1] to [5], further comprising seaweed polyphenols.

[0031] [7] An anti-obesity composition comprising a Salacia plant extract, a green tea extract and a Paeonia lactiflora extract.

[0032] [8] The anti-obesity composition according to [7], wherein

[0033] The mass ratio of the Salacia plant extract, the green tea extract and the African cardamom extract is 1-50:3-30:1-5.

[0034] [9] The anti-obesity composition according to [7] or [8], wherein

[0035] The active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarracenol, epigallocatechin gallate and 6-aframomide, respectively, and the daily intake of these is 0.2-1.5 mg, 10-100 mg and 1-5 mg, respectively.

[0036]

[10] The anti-obesity composition according to [7] or [8], wherein

[0037] The active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarracenol, epigallocatechin gallate and 6-aframomide, respectively, and the daily intakes thereof are 0.04 to 2.1 mg, 10 to 100 mg and 1 to 5 mg, respectively.

[0038]

[11] The anti-obesity composition according to any one of [7] to

[10] , wherein

[0039] Green tea extract is epigallocatechin gallate.

[0040]

[12] The anti-obesity composition according to any one of [7] to

[11] , further comprising seaweed polyphenol.

[0041] [A1] An oral composition comprising sarasinovol, epigallocatechin gallate and 6-aframyristol.

[0042] [A2] An oral composition comprising sarasinovol, epigallocatechin gallate and 6-aframyristol, wherein:

[0043] The mass ratio of sarasinovol, epigallocatechin gallate and 6-africanol is 1-50:3-30:1-5.

[0044] [A3] An oral composition comprising saracinol, epigallocatechin gallate and 6-aframyristol, wherein:

[0045] These are used in daily intakes of 0.2 to 1.5 mg, 10 to 100 mg, and 1 to 5 mg, respectively.

[0046] [A4] An oral composition comprising sarasinovol, epigallocatechin gallate and 6-aframyristol, wherein:

[0047] These are used in daily intakes of 0.04 to 2.1 mg, 10 to 100 mg, and 1 to 5 mg, respectively.

[0048] [A5] The oral composition according to any one of [A1] to [A4], further comprising seaweed polyphenol.

[0049] [A6] The oral composition according to any one of [A1] to [A5], further comprising brown algae polyphenols.

[0050] Effects of the Invention

[0051] According to the present invention, there is provided an oral composition (e.g., a food composition or an anti-obesity composition) that can reduce at least one of body weight, body fat percentage, BMI, waist circumference and abdominal fat area (visceral fat area, subcutaneous fat area, total fat area) with a small daily intake. DETAILED DESCRIPTION

[0052] The following are definitions of terms used in this specification.

[0053] “Process” includes not only independent processes but also processes that cannot be clearly distinguished from other processes as long as the intended purpose of the process is achieved.

[0054] “ to ” indicates a range including the numerical values ​​described before and after it as the minimum value and the maximum value, respectively.

[0055] "Daily intake" refers to the amount ingested by the subject of administration in one day, preferably refers to the amount ingested by an adult (more preferably a healthy adult) in one day. Daily intake has the same meaning as the daily dosage or the daily intake reference amount. The subject of administration is an animal (preferably a mammal) including a human.

[0056] "BMI" is the Body Mass Index, which is a value calculated by [weight (kg)] ÷ [height (m) squared], and is used to determine obesity or underweight. When the BMI is 22, it is a normal weight, and when the BMI exceeds 25, it is equivalent to obesity.

[0057] In the present specification, the composition of the present invention (including the case where it is simply referred to as "composition") refers to an oral composition, specifically, a food composition or a pharmaceutical composition. The composition of the present invention is preferably used as an anti-obesity composition.

[0058] The food composition involved in the present invention is a food composition selected from the group consisting of supplements, health foods, functional display foods, health functional foods, specific health foods, nutritional functional foods, nutritional supplement foods, health supplement foods, beverages, seasonings, preservatives and additives.

[0059] The anti-obesity composition of the present invention is an oral composition (preferably a food composition or a pharmaceutical composition) for treating, preventing, alleviating or improving a condition associated with obesity. A pharmaceutical composition refers to a pharmaceutical composition for treating, preventing, alleviating or improving a disease or condition by administering it to a subject such as a human.

[0060] When a plurality of substances corresponding to each component are present in the composition, the amount of each component in the composition means the total amount of the plurality of substances present in the composition unless otherwise specified.

[0061] Hereinafter, the present invention will be described.

[0062] The present invention relates to an oral composition containing a Salacia plant extract, a green tea extract and a African cardamom extract.

[0063] In the composition of the present invention, the mass ratio of the Salacia plant extract, the green tea extract and the Aframomum melegueta extract is preferably 1-50:3-30:1-5.

[0064] In the composition of the present invention, the mass ratio of the Salacia plant extract, the green tea extract and the Aframomum melegueta extract is more preferably 1-10:2-10:1-5.

[0065] In the composition of the present invention, it is preferred that the green tea extract is epigallocatechin gallate.

[0066] The composition of the present invention preferably further contains seaweed polyphenol (preferably brown algae polyphenol).

[0067] In the composition of the present invention, it is preferred that the active ingredients of the Salacia plant extract, green tea extract and Aframomum melongena extract are saracinol, epigallocatechin gallate and 6-aframomyl alcohol, respectively, and that they are used in a manner in which the daily intake of these ingredients is 0.2 to 1.5 mg, 10 to 100 mg and 1 to 5 mg, respectively. In other words, it is preferred that the active ingredients contained in the Salacia plant extract, green tea extract and Aframomum melongena extract, namely saracinol, epigallocatechin gallate and 6-aframomyl alcohol, are converted to each other, and that they are used in a manner in which the daily intake of these ingredients is 0.2 to 1.5 mg, 10 to 100 mg and 1 to 5 mg, respectively.

[0068] In another embodiment of the present invention, in the composition of the present invention, it is preferred that the active ingredients of the Salacia plant extract, green tea extract and Aframomum melongena extract are saracinol, epigallocatechin gallate and 6-aframomum alcohol, respectively, and they are used in a manner in which the daily intake of these is 0.04 to 2.1 mg, 10 to 100 mg and 1 to 5 mg, respectively. In other words, it is preferred that the active ingredients contained in the Salacia plant extract, green tea extract and Aframomum melongena extract, namely saracinol, epigallocatechin gallate and 6-aframomum alcohol, are converted to each other, and they are used in a manner in which the daily intake of these is 0.04 to 2.1 mg, 10 to 100 mg and 1 to 5 mg, respectively.

[0069] In the composition of the present invention, it is preferred that the active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarasinovol, epigallocatechin gallate and 6-aframomide, respectively, and they are used in a daily intake of 0.2-1.5 mg, 10-80 mg and 1-5 mg, respectively.

[0070] In another embodiment of the present invention, in the composition of the present invention, the active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are preferably saracinol, epigallocatechin gallate and 6-aframomide, respectively, and they are used in a manner such that the daily intake thereof is 0.1 to 1.8 mg, 10 to 80 mg and 1 to 5 mg, respectively.

[0071] In the composition of the present invention, it is preferred that the active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarasinovol, epigallocatechin gallate and 6-aframomide, respectively, and they are used in a daily intake of 0.2-1.5 mg, 10-60 mg and 1-5 mg, respectively.

[0072] In the composition of the present invention, the content of functional related components as a daily intake is preferably 1.0 mg / day of Saracino.

[0073] Epigallocatechin gallate 30 mg / day

[0074] 6-African myristol 3.75 mg / day.

[0075] In addition, in this specification, the functionally related components and the active ingredients have the same meanings.

[0076] In another embodiment of the present invention, the content of the functionally related components in the composition of the present invention as a daily intake is preferably

[0077] Saracino 1.0 mg / day

[0078] Epigallocatechin gallate 30 mg / day

[0079] 6-African myristol 2.8 mg / day.

[0080] In addition, in this specification, the functionally related components and the active ingredients have the same meanings.

[0081] In the composition of the present invention, the content of functional related components as a daily intake is preferably 1.0 mg / day of Saracino.

[0082] Epigallocatechin gallate 30 mg / day

[0083] 6-African myristyl alcohol 3.75 mg / day

[0084] Brown algae polyphenols 4.5 mg / day.

[0085] In another embodiment of the present invention, the content of the functionally related components in the composition of the present invention as a daily intake is preferably

[0086] Saracino 1.0 mg / day

[0087] Epigallocatechin gallate 30 mg / day

[0088] 6-African myristol 2.8 mg / day

[0089] Brown algae polyphenols 4.5 mg / day.

[0090] In the present invention, from the viewpoint of easy ingestion, the daily intake of the composition is preferably 500 to 1200 mg in total weight.

[0091] In the supplement disclosed in non-patent document 1, dietary fiber (related component: 760 mg or 800 mg of indigestible dextrin (dietary fiber)) is added as an active ingredient. However, in the composition of the present invention, the daily intake of salacia plant extract is 0.2 to 1.5 mg in terms of sarracenolide, while the daily intake of green tea extract is 10 to 100 mg in terms of epigallocatechin gallate and the daily intake of Aframomum melegueta extract is 1 to 5 mg in terms of 6-Aframomide. Compared with the supplement disclosed in non-patent document 1, the total intake of active ingredients is small. Even if the intake of active ingredients is small, in the composition of the present invention, as described later, a significant reduction in the fat area in the abdomen (visceral fat area, subcutaneous fat area, total fat area) is observed compared with the supplement disclosed in non-patent document 1. This is an unexpected effect.

[0092] In another embodiment of the present invention, in the composition of the present invention, the daily intake of the Salacia plant extract converted to sarracenolide is 0.04 to 2.1 mg, while the daily intake of the green tea extract converted to epigallocatechin gallate is 10 to 100 mg and the daily intake of the Aframomum melegueta extract converted to 6-Aframomide is 1 to 5 mg, and the total intake of the active ingredient is small compared with the supplement disclosed in Non-Patent Document 1. Even if the intake of the active ingredient is small, in the composition of the present invention, as described later, a significant reduction in the fat area in the abdomen (visceral fat area, subcutaneous fat area, total fat area) is observed compared with the supplement disclosed in Non-Patent Document 1. This is an unexpected effect.

[0093] The composition of the present invention preferably does not contain indigestible dextrin (dietary fiber). The composition of the present invention preferably does not contain monoglucosyl rutin. The composition of the present invention more preferably does not contain indigestible dextrin (dietary fiber) and monoglucosyl rutin.

[0094] In order not to increase the blood sugar level, the composition of the present invention preferably does not contain sugar as the main component (51% by mass or more and less than 100% by mass of the composition). The sugar is granulated sugar (sucrose), glucose (Glucose), maltose (Maltose), fructose, starch syrup, isomerized sugar (glucose fructose liquid sugar, fructose glucose liquid sugar, high fructose liquid sugar), lactose (Lactose), isomaltooligosaccharide, oligofructose (new sugar, inulin), oligogalactose (soybean oligosaccharide), oligoxylose, oligolacto-fructose (Lactosucrose), raffinose, trehalose and isomerized lactose (lactulose, oligolacto-oligosaccharide) one or more.

[0095] In order not to increase the daily intake, the composition of the present invention preferably does not contain sugar alcohol as the main component (51% by mass or more and less than 100% by mass of the composition). Sugar alcohol is one or more of sorbitol, mannitol, maltitol, and reduced starch syrup. In the composition of the present invention, it is more preferred not to contain maltitol or sorbitol as the main component (51% by mass or more and less than 100% by mass of the composition), and it is further preferred to contain 0% by mass or more and less than 30% by mass of maltitol and sorbitol, and it is particularly preferred to contain 0% by mass or more and less than 25% by mass of maltitol and sorbitol.

[0096] The composition of the present invention can reduce at least one of body fat percentage, BMI, waist circumference and abdominal fat area (visceral fat area, subcutaneous fat area, total fat area) by taking a small amount. Although its effect is not clear, it is speculated as follows.

[0097] The composition of the present invention contains Salacia plant extract, green tea extract and Aframomum melegueta extract.

[0098] It is believed that the Salacia plant extract (preferably Saracino) has an activity of inhibiting the action of α-glucosidase and inhibits the decomposition of sugars such as disaccharides and oligosaccharides present in the intestine into monosaccharides, thereby delaying the absorption of sugars.

[0099] Green tea extract (preferably catechins, more preferably epigallocatechin gallate) is believed to have an effect of inhibiting the decomposition and absorption of lipids. In addition, epigallocatechin gallate is believed to activate the effect of promoting fat burning and the effect of metabolizing lipids produced by burning in the liver (β-oxidation).

[0100] It is considered that the Aframomum melegueta extract (preferably 6-Aframomide) has the effect of activating brown adipocytes that burn fat in the body to generate heat or increasing beige adipocytes, which are cells such as brown adipocytes, to improve energy consumption.

[0101] The composition of the present invention is believed to have the function of inhibiting the absorption of sugars and lipids ingested from diets, feeds, etc. by animals including humans, and the function of inhibiting the absorption of fat, and through this function, it causes the activation of body metabolism and the inhibition of fat accumulation, thereby reducing abdominal fat (body fat, visceral fat) in people with high BMI (BMI exceeds 25), reducing body weight and lowering BMI.

[0102] However, the present invention is not limited by this assumption.

[0103] The composition of the present invention comprises a Salacia plant extract.

[0104] The genus Salacia is a plant of the family Pteridaceae that grows spontaneously mainly in Sri Lanka, India, and Southeast Asia. More specifically, one or more plants selected from the group consisting of Salacia reticulata, Salacia oblonga, Salacia prinoides, Salacia chinensis, Salacia cialatifolia, Salacia burunoniana, Salacia grandiflora, and Salacia macrosperma can be cited. As the genus Salacia, at least one plant selected from the group consisting of Salacia reticulata, Salacia oblonga, and Salacia chinensis can be preferably selected. The material obtained by crushing these plants, and extracts (preferably extract powders) extracted from the parts such as roots, stems, leaves, flowers, and fruits can be used. Furthermore, one or more parts may be used in combination. It is more preferable to use an extract extracted from a root or a stem.

[0105] In the present specification, the extract of Salacia plant and the crushed material of Salacia plant are used to mean the extract and / or crushed material containing the edible parts of Salacia plant such as roots, stems, leaves, flowers, fruits, etc., and the dried material of the above-mentioned extract and / or crushed material. In the present specification, the dry material may also be a dry powder (extract powder). When preparing the above-mentioned extract and / or crushed material of Salacia plant, more than one part of Salacia plant may be mixed for use. From the viewpoint of effectively manufacturing a purified Salacia plant extract, as a raw material extract containing Salacia plant, it is preferred to use an extract powder obtained by extracting a Salacia plant (extract) or a dry extract selected from a part selected from roots and stems.

[0106] The dry powder (extract powder) is preferably obtained by extracting the edible part of the Salacia plant or the like with a solvent and drying the extract obtained in the above process.

[0107] As the solvent used in the extraction, water, alcohol or ketone etc. can be mentioned, and a mixed solvent obtained by mixing two or more of them can also be used. As the alcohol, methanol or ethanol etc. can be mentioned, and ethanol is preferred. As the ketone, acetone, methyl ethyl ketone or cyclohexane etc. are preferred.

[0108] Among the above, water, alcohol, a mixed solvent of water and alcohol, or a mixed solvent of water and ketone is preferred, water, alcohol, or a mixed solvent of water and alcohol is more preferred, and hot water at 50° C. to 98° C., ethanol, or a mixed solvent of water and ethanol is further preferred. The alcohol content in the mixed solvent of water and alcohol is preferably 30% to 90% by mass, and more preferably 40% to 70% by mass.

[0109] The drying method of the dry powder (extract powder) is not particularly limited. The dry powder (extract powder) can be obtained by drying the solvent contained in the extract obtained above. Examples of the drying method include known drying methods such as spray drying and freeze drying.

[0110] The Salacia plant extract contains Saracino. The content of Saracino in the composition can be measured using a known method such as high-performance liquid chromatography.

[0111] For example, it can be confirmed under the following conditions.

[0112] Column: Shodex Asahipak NH2P-504E

[0113] Flow rate: 1 mL / min Eluent: 80% acetonitrile

[0114] Oven temperature: 30℃

[0115] Injection volume: 25μ L

[0116] Detector: Charged Aerosol Detector (CAD)

[0117] In the present invention, when the name of a functionally related component related to the Salacia plant extract, a component having a health function, a related component or an active ingredient is displayed, it is preferably displayed as Saracino or Saracino derived from Salacia.

[0118] In the present invention, when the Salacia plant extract is incorporated into the composition, the daily intake of the Salacia plant extract (preferably the daily intake per adult) is preferably within the range of 1 to 1000 mg.

[0119] In the present invention, when the Salacia plant extract is added to the composition, the daily intake (preferably the daily intake per adult) is preferably within the range of 0.2 to 1.5 mg in terms of sarracenol.

[0120] In the present invention, when the Salacia plant extract is added to the composition, the daily intake (preferably the daily intake per adult) is preferably within the range of 0.04 to 2.1 mg in terms of sarracenolide.

[0121] Green tea extract contains catechins, which are single or multiple components selected from catechin, epicatechin, gallocatechin, epigallocatechin, catechin gallate, epicatechin gallate, gallocatechin gallate, or epigallocatechin gallate.

[0122] The catechins in the present invention preferably include epigallocatechin gallate.

[0123] The green tea extract in the present invention can be obtained by extracting green tea, or commercially available green tea extracts can be used. Commercially available green tea extracts include, for example, "Sunphenon EGCG-0P", "Sunphenon 90MB-0P" (trade names, manufactured by Taiyo Kagaku Co., Ltd.), "Tea Fran 30A", "Tea Fran 90S" (trade names, manufactured by ITO EN, LTD.), etc.

[0124] In the present invention, when a green tea extract is added to the composition, the daily intake of the green tea extract (preferably the daily intake per adult) is preferably within a range of 10 mg to 10 g.

[0125] In the present invention, when a green tea extract is formulated into a composition, it is preferred that the daily intake (preferably the daily intake per adult) be set within the range of 10 to 100 mg, more preferably within the range of 10 to 80 mg, and even more preferably within the range of 10 to 60 mg, calculated as epigallocatechin gallate.

[0126] The African cardamom extract is extracted from African cardamom (Aframomum melegueta) which is a plant of the ginger family. The African cardamom extract contains 6-Aframomum alcohol (6-Paradol, 1-(4-hydroxy-3-methoxyphenyl)decan-3-one) as an active ingredient that promotes fat decomposition and inhibits weight gain.

[0127] [Chemical formula 1]

[0128]

[0129] The African cardamom extract is obtained by extracting from the root, stem, leaf, flower, seed, etc. of African cardamom by a known method. The solvent used for the extraction is not particularly limited, and for example, various organic solvents such as water, alcohols such as methanol, ethanol, propanol, isopropanol, and butanol, acetone, ethyl acetate, and hexane can be used, and a mixed solvent obtained by mixing two or more of these can also be used.

[0130] The Aframomum meliloti extract contains 6-Aframomimeticol. The content of 6-Aframomimeticol can be measured using a known method such as high performance liquid chromatography.

[0131] The Aframomum melongena extract of the present invention can be obtained by solvent extraction from Aframomum melongena.

[0132] In the present invention, when the African cardamom extract is added to the composition, the African cardamom extract is a stimulating substance, so it is preferred to reduce the daily intake while exerting the desired function (for example, anti-obesity effects such as promoting fat decomposition and inhibiting weight gain). The daily intake of the African cardamom extract (preferably the daily intake per adult) is preferably set in the range of 1 to 1000 mg.

[0133] In the present invention, when the Aframomum melegueta extract is added to the composition, the daily intake (preferably the daily intake per adult) is preferably within the range of 1 to 5 mg, more preferably within the range of 1 to 4 mg, calculated as 6-Aframomide.

[0134] The seaweed polyphenol in the present invention is a general term for polyphenols extracted from seaweed or components containing polyphenols, and contains brown algae polyphenols (e.g., phloroglucinol and polymers thereof, etc.) as a main component. As seaweed, brown algae are preferred, for example, algae of the genus Ascophyllum, kelp, sargassum, black kelp, kelp, kelp, etc. can be cited. From the aspect of the effect of inhibiting lipid absorption, algae of the genus Ascophyllum are preferred, and Ascophyllum nodsum is particularly preferred.

[0135] As an extraction solvent that can be used to extract seaweed polyphenols, water or an organic solvent, or a mixture thereof can be used. As an organic solvent, for example, lower alcohols with carbon atoms of 1 to 4 such as methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, sec-butanol, tert-butanol, polar organic solvents such as ketones such as dimethyl ketone, methyl ethyl ketone, acetone and methyl isobutyl ketone, methyl acetate, ethyl acetate, butyl acetate or diethyl ether, and non-polar organic solvents. Moreover, a mixture of these polar organic solvents and non-polar organic solvents appropriately combined can also be used. As an extraction method for obtaining an extract, known methods such as extraction based on immersion, heating extraction, continuous extraction or supercritical extraction can be cited. The extract can be concentrated by a known method afterwards. The obtained extract or concentrate can be further purified by a known method. As a purification method, ultrafiltration, adsorption resin treatment, molecular chromatography, partition chromatography or liquid-liquid extraction can be cited. In the present invention, brown algae polyphenols preferably have lipase inhibitory activity. Examples of methods for producing seaweed polyphenols include methods described in paragraphs

[0017] ,

[0018] , and

[0021] of JP-A-2005-170836.

[0136] As seaweed polyphenols, from the viewpoint of the lipid absorption inhibitory effect, the lipase 50% inhibition concentration (IC 50 The IC value is preferably 0.0001 μg / ml to 50 μg / ml, and more preferably 0.001 μg / ml to 10 μg / ml. If the IC value is 50 μg / ml or less, 50 The 50% inhibition concentration of lipase can be measured, for example, according to the method described in paragraph

[0019] of Japanese Unexamined Patent Publication No. 2005-170836. The IC value of lipase is 50 The value varies depending on the extraction method of the extract, etc.

[0137] Examples of the seaweed polyphenol in the present invention include commercially available products such as “seaweed polyphenol” (derived from Ascophyllum nodosum, manufactured by RIKEN VITAMIN CO., LTD.).

[0138] The content of seaweed polyphenol in the composition varies depending on the dosage form or administration method of the composition. For example, the daily intake of seaweed polyphenol (preferably the daily intake per adult) can be set to a range of 1 to 1000 mg, but there is no particular limitation. The daily intake of seaweed polyphenol (preferably the daily intake per adult) can be converted into brown algae polyphenol and set to 1 mg to 100 mg, preferably 1 mg to 50 mg, and more preferably 1 mg to 10 mg, but there is no particular limitation.

[0139] Furthermore, the composition of the present invention may further contain, in addition to the above-mentioned components, a carrier acceptable for food or medicine, or other known or well-known additive components.

[0140] The composition of the present invention may be in any form of liquid, solid, powder, or gel, and may be in the form of a solution, tablet, capsule (hard capsule, soft capsule), granule, or the like.

[0141] When the composition of the present invention is in the form of a solution, an aqueous medium such as water can be preferably used as a carrier. When it is made into a solid form, excipients such as crystalline cellulose and magnesium stearate, and swelling agents such as corn starch and alginic acid can be preferably used as additives. In addition, as a coating agent for tablets, capsules, and granules, shellac, sugar, film coating substrates, yeast walls, etc. can be used.

[0142] In the composition of the present invention, in order to make the Salacia plant extract, green tea extract or African cardamom extract easy to disperse, it is preferably contained less than 30% by mass (preferably 0.01% by mass or more and less than 25% by mass) of reduced starch syrup. By containing reduced starch syrup, when the composition of the present invention is a tablet, it can be made into a tablet that has a good tongue feel and is easy to drink. In addition, when the composition of the present invention contains reduced starch syrup, the Salacia plant extract, green tea extract or African cardamom extract contained in the composition of the present invention is easy to maintain stability.

[0143] Reduced starch syrup is a type of sugar alcohol, synthesized by reducing (i.e., hydrogenating) starch syrup. Reduced starch syrup can adjust the viscosity by changing the composition of starch syrup (i.e., sugar) as a raw material, and is classified into high-saccharification reduced starch syrup and low-saccharification reduced starch syrup. In addition, a maltitol content of 50% or more per unit solid content is called maltitol syrup, and a maltitol content of 75% or more per unit solid content is called reduced maltose starch syrup. From the viewpoint of the dispersibility and stability of the Salacia plant extract, green tea extract, or African cardamom extract in the composition of the present invention, it is preferred to use reduced maltose starch syrup.

[0144] The reduced starch syrup is particularly preferably a reduced maltose starch syrup having a high degree of saccharification.

[0145] Commercially available examples of reduced starch syrups include OLIGOTOSE (manufactured by Sanwa Starch Co., Ltd.), OLIGOTOSE (trade name, manufactured by B Food Science Co., Ltd.), SE30 (trade name, manufactured by B Food Science Co., Ltd.), SE100 (trade name, manufactured by B Food Science Co., Ltd.), MALBIT (trade name, manufactured by B Food Science Co., Ltd.), AMALTY (registered trademark) MR-50 (trade name, manufactured by Mitsubishi Corporation Life Sciences Limited), OLIGOTOSE H-70 (trade name, manufactured by Mitsubishi Chemical Foods Co., Ltd.), HALLODEX (trade name, manufactured by Hayashibara Co., Ltd.), TETRUPP (trade name, manufactured by Hayashibara Co., Ltd.), TETRUPP-H (trade name, manufactured by Hayashibara Co., Ltd., manufactured), PENTRUP (trade name, manufactured by Hayashibara Co., Ltd.,), COUPLING SUGAR (trade name, manufactured by Hayashibara Co., Ltd.,), COUPLING SUGAR S (trade name, manufactured by Hayashibara Co., Ltd.,), etc.

[0146] The composition of the present invention can further include at least one of calcium carbonate and silicon dioxide. Thus, the discoloration of the components contained in the food composition over time can be prevented, and in particular, when the extract of the genus Salacia is contained, the discoloration of the extract of the genus Salacia over time can be suppressed. The content of calcium carbonate or silicon dioxide in the composition also varies depending on the dosage form of the composition. When the dosage form of the composition is in the form of a tablet or a hard capsule, the content of calcium carbonate is preferably 0.5% to 2.5% by mass of the composition, and the content of silicon dioxide is preferably 0.5% to 2.0% by mass of the composition. In addition, when calcium carbonate and particulate silicon dioxide are used in combination, the ratio of calcium carbonate to silicon dioxide can be used in the range of 1:0.15 to 1:0.10 on a mass basis.

[0147] The composition of the present invention can further use low hygroscopic raw materials and hygroscopic agents. As low hygroscopic raw materials, cellulose, crystalline cellulose, powdered cellulose, microcrystalline cellulose, lactose, sugar alcohol, trehalose, magnesium stearate, calcium stearate, etc. are preferably used. As hygroscopic agents, silicates, magnesium carbonate, ferrocyanide, polysaccharides, etc. are used. As low hygroscopic raw materials, crystalline cellulose, microcrystalline cellulose, lactose are more preferably used. In addition, as compounds required for molding into powders, solids or solutions, erythritol, maltitol, hydroxypropyl cellulose, kaolin, talc, etc. can be cited. In addition, as other lipid absorption inhibiting ingredients, black oolong tea polyphenols, onion peel extract, red wine polyphenols, coffee bean oligomannosaccharides, orlistat, carambola extract, wheat extract, etc. can be used in combination.

[0148] The food composition of the present invention is preferably used as a health food, a supplement or a functional display food. Health food, a supplement or a functional display food is a food that is taken orally other than medicines and contributes to the maintenance / improvement of health or is taken in anticipation of such an effect / function. A supplement refers to a food in the form of a tablet or capsule containing a specific active ingredient. A functional display food refers to a food that displays functionality based on scientific evidence under the responsibility of the operator, and is a food that has reported information related to the basis of safety and functionality to the Consumer Affairs Agency before sale. As the functionality of a food, a tertiary function can be cited. The tertiary function refers to the role of repairing the modulation of the physiological function of an organism (physical condition regulating function).

[0149] Example

[0150] The present invention will be described in detail below using examples. However, the present invention is not limited to these examples. In addition, "%" is based on mass unless otherwise specified.

[0151] [Example 1 to Example 2, Comparative Example 1]

[0152] (Test diet and intake method)

[0153] Two test diets (Examples 1 and 2) were prepared, and one control diet (Comparative Example 1) was prepared. As test diets, tablets of compound ingredient supplement A prepared with saracinol, epigallocatechin gallate, and 6-africanol (hereinafter, test diet A: Example 1) and tablets of compound ingredient supplement B prepared with saracinol, epigallocatechin gallate, 6-africanol, and brown algae polyphenols (hereinafter, test diet B: Example 2) were prepared. As a control diet (Comparative Example 1), tablets using excipients and color regulators that do not affect obesity or intestinal environment were prepared (Table 1). It was confirmed that the test diets could not be distinguished from each other in appearance, flavor, color, etc., and were provided for the test.

[0154] For both the test diet and the control diet, 6 capsules were taken per day, 2 capsules each day before breakfast, lunch, and dinner (30 minutes to 5 minutes before each meal) with water or boiled water without chewing.

[0155] [Table 1]

[0156]

[0157] (Test schedule)

[0158] The test period was set to 8 weeks, and the evaluation was performed 6 weeks or 8 weeks after the intake.

[0159] (Inspection Items)

[0160] The following measurements were performed before (week 0) or after 6 or 8 weeks of the test diet. Only the intestinal flora was measured because early changes may affect body weight, etc., so measurements were also performed after 2 weeks of the diet.

[0161] 1) Body measurement and physiological examination

[0162] As physical measurements, height, weight, BMI, body fat percentage, and waist circumference were measured, and as physiological examinations, body temperature, systolic blood pressure, diastolic blood pressure, and pulse rate were measured.

[0163] 2) Hematology test, blood biochemistry test, urine test

[0164] Hematological examinations (white blood cell count, red blood cell count, hemoglobin level, hematocrit value, platelet count) and blood biochemistry tests (total protein, albumin, total bilirubin, AST (GOT), ALT (GPT), LDH, ALP, γ-GT, CPK, total cholesterol, HDL-cholesterol, LDL-cholesterol, neutral fat, fasting blood glucose, uric acid, urea nitrogen, creatinine, Na, Cl, K, Ca, HbA1c) and urine tests (specific gravity, pH, qualitative protein, qualitative sugar, occult blood reaction, qualitative urobilinogen, qualitative bilirubin) were performed.

[0165] 3) Abdominal fat area

[0166] To measure the abdominal visceral fat area, abdominal subcutaneous fat area, and abdominal total fat area, abdominal tomography was performed using a CT scanning system (Hitachi whole body X-ray device Robusto-Ei; Hitachi Medico Co., Ltd.). The images were analyzed using visceral fat measurement PC software (Fat Scan Premium; East Japan Institute of Technology Co., Ltd.), and the analysis results were recorded in the case report.

[0167] 4) Survey on diet and exercise

[0168] A dietary survey was conducted 5 to 3 days before each visit. Specifically, based on the dietary questionnaire submitted by the trial participants and the dietary photos taken by the trial participants, the nutritionist used nutrition analysis software (Excel Eiyo-Kun (R) ver. 9: KENPAKUSHA Co., Ltd.) to analyze and calculate the energy, protein, fat, and carbohydrate content. The analysis results were output to the case report.

[0169] Regarding the physical activity survey, the test participants were asked to carry a pedometer (FB-740: manufactured by TANITA Corporation) 5 to 3 days before each visit, and the number of steps measured was entered in a dietary questionnaire.

[0170] 5) Stool analysis

[0171] Feces were collected 2 to 1 day before each visit to the hospital, and intestinal flora was analyzed by amplicon sequence analysis.

[0172] The participants were defined as those aged 20 years and above but less than 64 years, and their BMI at screening was 23.0 kg / m 2 Above and less than 30.0kg / m 2 The participants were selected by setting exclusion criteria (for example, those who met the diagnostic criteria for metabolic syndrome, those who gained or lost more than 5% of their weight within six months from the start of the trial, and other persons who were judged by the responsible physician of the trial as unsuitable for participation in this trial, etc.). In addition, those who were judged as inappropriate as analysis subjects of the trial were excluded, and 67 people were used as analysis subjects for Per Protocol Set (PPS: per protocol set) analysis (control diet: 23 people, test diet A: 22 people, test diet B: 22 people). The intake rate of the tested food exceeded 99% in each group, and there was no difference in the intake rate between the groups. In the background data of the trial participants, there was no significant difference between the groups before intake (Table 2).

[0173] [Table 2]

[0174]

[0175] The results of the experiments on abdominal visceral fat, subcutaneous fat, and total fat area were summarized (Table 3). No significant differences were found between the groups for the measured values ​​at week 0 for abdominal visceral fat, subcutaneous fat, and total fat area. In the control diet group, a significant increase was found in subcutaneous fat area at week 6 compared to week 0.

[0176] In the test diet A group, significant decreases in visceral fat and total fat area were observed after 6 weeks of intake compared to week 0. In addition, significant decreases in subcutaneous fat area and total fat area were observed after 6 weeks of intake compared to the control diet group.

[0177] In the test diet B group, significant decreases in subcutaneous fat and total fat area were observed at 6 weeks compared to 0 weeks.

[0178] [Table 3]

[0179]

[0180] The results of weight, BMI, body fat percentage, and waist circumference are shown (Table 4). Regarding weight, BMI, body fat percentage, and waist circumference, no significant differences were found between the groups with respect to the measured values ​​at week 0.

[0181] Regarding body weight, in the control diet group, there was no change at 0 week, after 6 weeks of intake, and after 8 weeks of intake. On the other hand, after 6 and 8 weeks of the test diet A and B groups, a significant decrease in the measured values ​​when compared with the measured values ​​at 0 week and a significant decrease in the change compared with the control diet group were shown.

[0182] In the control diet group, there was no change in BMI after 0 weeks, 6 weeks, and 8 weeks of intake. In the test diet A and B groups, the measured values ​​after 6 and 8 weeks of intake were significantly reduced. Moreover, in the comparison of the amount of change, the BMI was significantly reduced after 6 and 8 weeks of intake compared to the control diet group, and a significant difference between the groups was confirmed.

[0183] Regarding body fat percentage, a significant decrease was observed in the 8th week of the test diet A group and in the 6th week of the test diet B group compared to the initial values.

[0184] Regarding waist circumference, no significant changes before and after intake were observed in the control diet group, but in the experimental diet A and B groups, at the 8th week, the measured values ​​showed a significant decrease compared with the initial values, and the changes showed a significant decrease compared with the control diet group.

[0185] [Table 4]

[0186]

[0187] The results of intestinal flora determination are shown (Table 5). The presence ratios of Bifidobacterium, Lactobacillales, Bacteroidales, and Clostridiales were compared. No significant differences were confirmed between the groups for the measured values ​​at week 0.

[0188] After 2 weeks of intake, in the test diets A and B, the Bifidobacterium genus increased significantly both within and between groups, and the Bacteroidales order and Clostridiales order decreased significantly both within and between groups. In the test diet A group, the Lactobacillales family increased significantly both within and between groups. In the test diet B group, a significant increase in the Lactobacillales family was confirmed in the inter-group comparison, but no significant difference from the initial value of 2 weeks was confirmed. After 6 and 8 weeks of intake, in the test diet A and B groups, the Bifidobacterium genus and Lactobacillales family, which are preferred when improving the intestinal environment (intestinal flora), increased significantly both within and between groups. On the other hand, a decrease was confirmed in the Bacteroidales order and Clostridiales order both within and between groups.

[0189]

[0190] The results of blood pressure measurement are shown (Table 6). In the test diet A and B groups, the average of the measurements before and after the test (comparison of 0 weeks before and 8 weeks after the test diet intake) showed a tendency for both systolic blood pressure and diastolic blood pressure to decrease. In addition, in the test diet A and B groups, both systolic blood pressure and diastolic blood pressure showed a significant decrease compared to the control diet group.

[0191] [Table 6]

[0192]

[0193] Regarding the body fat percentage of the test participants in this test, the body fat percentage was 27.14% for men and 39.09% for women. Compared with the average body composition of Japanese adults, the 50-year-old men had a body fat percentage of 22.4% and the women had a body fat percentage of 29.4%, which is high. In addition, based on the abdominal fat area value, it is also believed that the test participants were in a state of excessive fat accumulation. The results of calculating the amount of fat reduced based on the body fat percentage after the test showed that the amount of fat reduced by about 500g in both the test diet A and B groups 6 weeks after the start of intake, and the amount of fat reduction was maintained for 8 weeks. If the amount of weight loss is considered, it is believed that the compound ingredient supplement almost selectively reduces only fat.

[0194] In addition, the state of long-term unchanged weight observed in the test subjects of this time refers to a state in which the energy intake is consistent with the energy required to maintain the body or life (basal metabolism, metabolism during sleep, diet-induced thermogenesis, etc.). In this test, a decrease in body weight and fat mass was confirmed at 6 weeks of intake. In addition, it is believed that if the body weight is reduced, the energy consumption is reduced due to the adaptation of the homeostatic metabolism, so under the condition of this test where the energy intake or exercise amount does not change, the recovery (rebound) of body weight occurs. However, it is believed that in this test, in the 8th week after the weight loss, compared with the control group, a state of significantly reduced body weight and fat mass was maintained, and by continuously consuming test meals A and B, a body that is not easy to grow excess fat, which is important in health, can be maintained.

[0195] From the above results, it was confirmed that the abdominal fat area (visceral fat area, subcutaneous fat area, total fat area), body weight, BMI, and waist circumference were reduced by taking test diet A (Example 1) or test diet B (Example 2).

[0196] Furthermore, it was found that by continuously consuming test diet A (Example 1) or test diet B (Example 2), a body that is less likely to gain excess fat can be maintained, the intestinal environment (intestinal flora) can be improved in advance, and an increase in blood pressure can be suppressed.

[0197] [Prescription Example]

[0198] The following are examples of the oral composition formulations of the present invention. The capsules are obtained by filling the inside of a gelatin capsule film with the components of the following tablet formulations by a conventional method.

[0199]

[0200]

[0201]

Claims

1. A food composition comprising a Salacia plant extract, a green tea extract and a African cardamom extract.

2. The food composition according to claim 1, wherein The mass ratio of the Salacia plant extract, the green tea extract and the Aframomum melegueta extract is 1-50:3-30:1-5.

3. The food composition according to claim 1 or 2, wherein The active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarracenol, epigallocatechin gallate and 6-aframomide, respectively, and the daily intake of these is 0.2-1.5 mg, 10-100 mg and 1-5 mg, respectively.

4. The food composition according to claim 1 or 2, wherein The active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarracenol, epigallocatechin gallate and 6-aframomide, respectively, and the daily intakes thereof are 0.04 to 2.1 mg, 10 to 100 mg and 1 to 5 mg, respectively.

5. The food composition according to claim 1 or 2, wherein Green tea extract is epigallocatechin gallate.

6. The food composition according to claim 1 or 2, wherein The food composition further contains seaweed polyphenols.

7. An anti-obesity composition comprising a Salacia plant extract, a green tea extract and a Aframomum melegueta extract.

8. The anti-obesity composition according to claim 7, wherein The mass ratio of the Salacia plant extract, the green tea extract and the Aframomum melegueta extract is 1-50:3-30:1-5.

9. The anti-obesity composition according to claim 7 or 8, wherein The active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarracenol, epigallocatechin gallate and 6-aframomide, respectively, and the daily intake of these is 0.2-1.5 mg, 10-100 mg and 1-5 mg, respectively.

10. The anti-obesity composition according to claim 7 or 8, wherein The active ingredients of the Salacia plant extract, green tea extract and Aframomum melegueta extract are sarracenol, epigallocatechin gallate and 6-aframomide, respectively, and the daily intakes thereof are 0.04 to 2.1 mg, 10 to 100 mg and 1 to 5 mg, respectively.

11. The anti-obesity composition according to claim 7 or 8, wherein Green tea extract is epigallocatechin gallate.

12. The anti-obesity composition according to claim 7 or 8, wherein The anti-obesity composition further contains seaweed polyphenols.

Images